Quick Answer
CRISPR Therapeutics AG reported Cash And Cash Equivalents At Carrying Value of $347.56 million for the year ending 2025.
- CRISPR Therapeutics AG showed an increase of +16.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $49.05 million | Q1 2016: $200.60 million | Q2 2016: $246.85 million | Q3 2016: $228.61 million | Q1 2017: $288.87 million | Q2 2017: $272.26 million | Q3 2017: $253.52 million | Q1 2018: $341.77 million | Q2 2018: $319.74 million | Q3 2018: $487.30 million | Q1 2019: $437.55 million | Q2 2019: $427.89 million | Q3 2019: $629.72 million | Q1 2020: $889.71 million | Q2 2020: $945.07 million | Q3 2020: $1.04 billion | Q1 2021: $1.13 billion | Q2 2021: $1.65 billion | Q3 2021: $1.01 billion | Q1 2022: $683.91 million | Q2 2022: $496.89 million | Q3 2022: $494.15 million | Q1 2023: $344.41 million | Q2 2023: $444.80 million | Q3 2023: $527.77 million | Q1 2024: $707.43 million | Q2 2024: $484.47 million | Q3 2024: $225.67 million | Q1 2025: $235.18 million | Q2 2025: $193.62 million | Q3 2025: $286.50 million.
- Over the full 13 years of available data (2013 to 2025), CRISPR Therapeutics AG's Cash And Cash Equivalents At Carrying Value has grown by 96,176.7%.
- Historical annual values: Fiscal year 2025: $347.56 million | Fiscal year 2024: $298.26 million | Fiscal year 2023: $389.48 million | Fiscal year 2022: $211.89 million | Fiscal year 2021: $923.03 million | Fiscal year 2020: $1.17 billion | Fiscal year 2019: $943.77 million | Fiscal year 2018: $456.65 million | Fiscal year 2017: $239.76 million | Fiscal year 2016: $315.52 million | Fiscal year 2015: $155.96 million | Fiscal year 2014: $945.0 thousand | Fiscal year 2013: $361.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: